Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

161. Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate Cancer: a systematic review and meta-analysis. (Full text)

Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate Cancer: a systematic review and meta-analysis. The application of multiparametric magnetic resonance imaging (mpMRI) for diagnosis of prostate cancer has been recommended by the European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN), and European Society of Urogenital Radiology (ESUR) guidelines. The purpose of this study is to systematically review the literature on assessing (...) the accuracy of mpMRI in patients with suspicion of prostate cancer.We searched Embase, Pubmed and Cochrane online databases from January 12,000 to October 272,018 to extract articles exploring the possibilities that the pre-biopsy mpMRI can enhance the diagnosis accuracy of prostate cancer. The numbers of true- and false-negative results and true- and false-positive ones were extracted to calculate the corresponding sensitivity and specificity of mpMRI. Study quality was assessed using QUADAS-2 tool

2020 BMC cancer PubMed abstract

162. Value of shear wave elastography for diagnosis of primary prostate cancer: a systematic review and meta-analysis. (Full text)

Value of shear wave elastography for diagnosis of primary prostate cancer: a systematic review and meta-analysis. To evaluate the difference in stiffness between prostate cancer (PCa) and benign tissue based on Young's modulus determined by shear wave elastography (SWE). In addition, the diagnostic accuracy of SWE for the detection of PCa was evaluated comprehensively.We conducted our systematic review and meta-analysis based on databases of PubMed, Embase and Web of Science. Relevant studies (...) regarding to the diagnostic accuracy of SWE for detecting PCa compared to a reference standard of histopathology were included. The pooled weighted mean difference (WMD) of Young's modulus, sensitivity (SEN) and specificity (SPE), and area under the curve (AUC) were calculated using Stata software.Based on our search strategy, 9 studies were ultimately included. The pooled results indicated that the mean Young's modulus for detecting prostate cancer was significantly higher than that for prostate benign

2020 Medical ultrasonography PubMed abstract

163. Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. (Abstract)

Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. The purpose of this study was to assess the prognostic value of hemoglobin (Hb) in patients with metastatic hormone-sensitive prostate cancer (HSPC). The PUBMED, Web of Science, Cochrane Library, and Scopus databases were searched in December 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible (...) if they compared patients with HSPC with normal and low Hb levels to determine their ability to predict overall survival, cancer-specific survival, progression-free survival, and castration-resistant prostate cancer-free survival. Formal meta-analyses were performed for these outcomes. The systematic review identified 25 studies including 6614 patients; 21 studies comprising 5782 patients were eligible for meta-analysis. Low Hb levels were associated with worse overall survival (pooled hazard ratio [HR], 1.21

2020 Clinical genitourinary cancer

164. Diagnostic Performance of PET/CT Using 18F-FACBC in Prostate Cancer: A Meta-Analysis. (Full text)

Diagnostic Performance of PET/CT Using 18F-FACBC in Prostate Cancer: A Meta-Analysis. Background: Diagnostic performance of PET/CT using 18F-fluciclovine (18F-FACBC) in patients with prostate cancer (PCa) has been evaluated in only a few studies. There is no consensus on the diagnostic value of 18F-FACBC PET/CT in PCa recurrence or metastasis (except for bone metastasis), the primary diagnosis of the lesion. Hence, a meta-analysis was conducted to evaluate the performance of 18F-FACBC PET/CT

2020 Frontiers in oncology PubMed abstract

165. Traditional Chinese medicine on treating pain caused by prostate cancer: A systematic review and meta-analysis. (Full text)

Traditional Chinese medicine on treating pain caused by prostate cancer: A systematic review and meta-analysis. Prostate cancer is a male malignant tumor disease with high prevalence in recent years. Patients with advanced prostate cancer are more likely to have bone metastasis and have strong bone pain, and even lead to pathological fracture, which has a serious impact on the quality of life of patients. Traditional Chinese medicine has good clinical efficacy in treating pain caused (...) by prostate cancer .This review hopes to adopt meta-analysis to evaluate the efficacy and safety of TCM in the treatment of pain caused by prostate cancer and provide evidence for its application in clinical practice.We will search for PubMed, Cochrane Library, AMED, EMbase, WorldSciNet; Nature, Science online and China Journal Full-text Database (CNKI), China Biomedical Literature CD-ROM Database (CBM), and related randomized controlled trials included in the China Resources Database. The time is limited

2020 Medicine PubMed abstract

166. Assessment of the efficacy of Chinese patent medicine on treating pain caused by prostate cancer: A protocol for systematic review and meta analysis. (Full text)

Assessment of the efficacy of Chinese patent medicine on treating pain caused by prostate cancer: A protocol for systematic review and meta analysis. With the development of economy and the acceleration of population aging, Prostate cancer (PCa) has presented a situation of high morbidity and mortality worldwide. The recent studies have shown that Chinese patent medicine combined with endocrine therapy in the treatment of prostate cancer not only plays a synergistic role in enhancing (...) the efficacy. This review hopes to adopt meta-analysis to evaluate the efficacy and safety of Chinese patent medicine in the treatment of pain caused by prostate cancer and provides evidence for its application in clinical practice.We will search for PubMed, Cochrane Library, AMED, EMbase, WorldSciNet; Nature, Science online and China Journal Full-text Database (CNKI), China Biomedical Literature CD-ROM Database (CBM), and related randomized controlled trials included in the China Resources Database

2020 Medicine PubMed abstract

167. Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: A systematic review and meta-analysis of randomized controlled trials. (Full text)

Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: A systematic review and meta-analysis of randomized controlled trials. Previous evidence directly evaluating the efficacy and safety of abiraterone and enzalutamide treatment for castration-resistant prostate cancer (CRPC) is limited. We aim to include more randomized controlled trials (RCTs) to comprehensively assess the efficacy and safety of abiraterone and enzalutamide treatment.PubMed, Embase (...) , and ClinicalTrial.gov were systematically searched. Pooled hazard ratios (HRs) were calculated using Stata 12.0 software. The comparison of the prostate-specific antigen (PSA) response rate and adverse events (AEs) between the treatment and control groups were performed using RevMan 5.3 software.Eight eligible RCTs with 6,490 patients were selected. Pooled HRs were 0.72 for overall survival, 0.45 for radiographic progression-free survival (rPFS), and 0.36 for PSA PFS. abiraterone and enzalutamide could

2020 Medicine PubMed abstract

168. Molecular Biomarkers in Localized Prostate Cancer

prognostic models and enhanced prebiopsy imaging are mandatory. An essential consideration when implementing any tissue-based biomarker study in prostate cancer is that tissue-based molecular testing is dependent on the site of collection within the primary tumor and tumor content, and is significantly influenced by the heterogeneity of the disease. , , For the purpose of improving prognostic value, it is of paramount importance to select the areas that are characterized by the most aggressive disease (...) . were Expert Panel co-chairs. Abstract Section: PURPOSE This guideline provides recommendations for available tissue-based prostate cancer biomarkers geared toward patient selection for active surveillance, identification of clinically significant disease, choice of postprostatectomy adjuvant versus salvage radiotherapy, and to address emerging questions such as the relative value of tissue biomarkers compared with magnetic resonance imaging. METHODS An ASCO multidisciplinary Expert Panel

2020 American Society of Clinical Oncology Guidelines

169. Apalutamide (Erleada) - non-metastatic castration-resistant prostate cancer (NM-CRPC)

Apalutamide (Erleada) - non-metastatic castration-resistant prostate cancer (NM-CRPC) Published 10 February 2020 Statement of advice SMC2268 apalutamide 60mg film-coated tablets (Erleada®) Janssen-Cilag Ltd 10 January 2020 ADVICE: in the absence of a submission from the holder of the marketing authorisation apalutamide (Erleada®) is not recommended for use within NHSScotland. Indication under review: In adult men for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC (...) ) who are at high risk of developing metastatic disease. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence

2020 Scottish Medicines Consortium

170. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer CUAJ • February 2020 • Volume 14, Issue 2 © 2020 Canadian Urological Association CUA gUideline 17 Cite as: Can Urol Assoc J 2020;14(2):17-23. http://dx.doi.org/10.5489/cuaj.6384 Published online December 5, 2019 Introduction Metastatic prostate cancer remains an incurable disease. In Canada, approximately 8% of men with prostate cancer are diagnosed (...) de novo with metastatic disease and, in 2018, roughly 1200 men were diagnosed with de novo metastat- ic prostate cancer (PC). 1 The mainstay of treatment for de novo metastatic PC is androgen-deprivation therapy (ADT), which is initially effective in almost all patients. Progression is inevitable, however, heralded by a rise in prostate-specific antigen (PSA), increasing disease burden, and/or worsening symptoms — a disease state called metastatic castration- resistant prostate cancer (mCRPC

2020 Canadian Urological Association

171. Bone Health and Bone-targeted Therapies for Prostate Cancer

for Prostate Cancer guideline. This guideline included recommendations across a relatively broad clinical spectrum within prostate cancer. Topics addressed ranged from management of osteoporotic fracture risk in nonmetastatic disease to management of men with castration-resistant prostate cancer metastatic to bone. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS The Bone Health and Bone-Targeted (...) -targeted therapies for prostate cancer. The CCO practice recommendations are drawn from data provided by randomized controlled trials (RCT) and systematic reviews of bone-targeted therapies in men with prostate cancer in a variety of settings. Relevant clinical risks range from osteoporotic fractures associated with androgen-deprivation therapy (ADT) to morbidity and death as a result of progression of bone-metastatic castration-resistant disease. In this document, the ASCO Expert Panel (Appendix

2020 American Society of Clinical Oncology Guidelines

172. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial (Abstract)

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial Abiraterone acetate plus prednisone and enzalutamide are both used for the treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best sequence in which to use both drugs, as well as their second-line efficacy.In this multicentre, randomised, open-label, phase 2, crossover (...) trial done in six cancer centres in British Columbia, Canada, we recruited patients aged 18 years or older with newly-diagnosed metastatic castration-resistant prostate cancer without neuroendocrine differentiation and Eastern Cooperative Oncology Group performance status 2 or less. Patients were randomly assigned (1:1) using a computer-generated random number table to receive either abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg orally twice daily until PSA progression followed

2020 EvidenceUpdates

173. Trends in Gene Expression Profiling for Prostate Cancer Risk Assessment: A Systematic Review. (Full text)

Trends in Gene Expression Profiling for Prostate Cancer Risk Assessment: A Systematic Review. The aim of the study is to review biotechnology advances in gene expression profiling on prostate cancer (PCa), focusing on experimental platform development and gene discovery, in relation to different study designs and outcomes in order to understand how they can be exploited to improve PCa diagnosis and clinical management.We conducted a systematic literature review on gene expression profiling

2020 Biomedicine hub PubMed abstract

174. The Effect of Prostate Cancer Radiotherapy on Testosterone Level: A Systematic Review and Meta-Analysis. (Abstract)

The Effect of Prostate Cancer Radiotherapy on Testosterone Level: A Systematic Review and Meta-Analysis. In the current study, a systematic search and meta-analysis was performed to evaluate the effect of prostate cancer radiotherapy on testosterone level of patients.To illuminate the effect of radiotherapy on the testosterone level of prostate cancer patients, a systematic search was conducted in accordance with the PRISMA guideline in electronic databases of Scopus, Embase, PubMed, Web (...) of Science, and clinical trials up to December 2018 using relevant keywords. Based on a certain set of inclusion and exclusion criteria, 12 eligible studies which had data on the testosterone level following prostate cancer radiotherapy were included in the meta-analysis.According to the various techniques of prostate cancer radiotherapy, the dose values scattered to the testicular tissues ranged from 0.31 to 10 Gy. Combining the findings from 12 studies, it was found that prostate cancer radiotherapy

2020 Anti-cancer agents in medicinal chemistry

175. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis. (Abstract)

Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis. To evaluate whether serum neuroendocrine markers could effectively predict treatment outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC).The PubMed, Cochrane Library and Embase databases were sought to identify eligible studies concerning serum neuroendocrine markers and the prognosis of post-treatment mCRPC from inception to April

2020 Urologia internationalis

176. Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis. (Abstract)

Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis. The diagnostic value and suitability of prostate cancer antigen 3 (PCA3) for the detection of prostate cancer (PCa) have been inconsistent in previous studies. Thus, the aim of the present meta-analysis was performed to systematically evaluate the diagnostic value of PCA3 for PCa.A meta-analysis was performed to search relevant studies using online databases EMBASE, PubMed and Web

2020 International braz j urol : official journal of the Brazilian Society of Urology

177. The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis. (Abstract)

The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis. To evaluate the effects of statin use on the treatment outcomes (i.e. overall survival and cancer-specific survival) among advanced prostate cancer (PCa) patients treated with androgen deprivation therapy (ADT) or abiraterone/enzalutamide.The original studies, examining the effects of statins on the outcomes (i.e. overall survival (...) significantly lowered the risk of all-cause mortality (100 709 patients, HR = 0.73, 95%CI = 0.64-0.83, P < .00001) and the risk of cancer-specific mortality (100 343 patients, HR = 0.64, 95% CI = 0.53-0.77, P < .00001) in advanced PCa patients treated with ADT. The sensitivity analysis showed that the results were reliable. However, it could not generate reliable evidence in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone/enzalutamide, as relevant studies were

2020 Journal of clinical pharmacy and therapeutics

178. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. (Abstract)

of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspected high-risk disease, newly diagnosed treatment (...) Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups.An Expert Panel was convened with members from ASCO and the Society

2020 Journal of clinical oncology : official journal of the American Society of Clinical Oncology

179. The expression of miR-375 in prostate cancer: A study based on GEO, TCGA data and bioinformatics analysis. (Abstract)

The expression of miR-375 in prostate cancer: A study based on GEO, TCGA data and bioinformatics analysis. MiR-375, as a member of miRNA family, plays essential roles in prostate cancer (PC). We purpose to explore the expression and possible molecular mechanism of the miR-375 in PC using database analysis.First, Student's t-test, overall and subgroup meta-analyses with 20 eligible datasets in the Gene Expression Omnibus (GEO) database were performed to explore the expression of miR-375 in PC (...) compared with non-cancerous group (SMD; 0.71; 95% CI: 0.38-1.04). In addition, the meta-analyses by subgroup showed the expression of miR-375 in PC tissues was higher than that in healthy prostate tissues and adjacent non-cancerous tissues. The results of TCGA database verified the expression of miR-375 in PC tissues was obviously higher than that in adjacent non-cancerous tissues. Moreover, GO and KEGG analysis revealed that the latent target genes were mainly involved in protein binding function

2020 Pathology, research and practice

180. Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. (Abstract)

occurred from January 2013 to August 2017.Patients were randomized to a counseling behavioral intervention by telephone promoting consumption of 7 or more daily vegetable servings (MEAL intervention; n = 237) or a control group, which received written information about diet and prostate cancer (n = 241).The primary outcome was time to progression; progression was defined as PSA level of 10 ng/mL or greater, PSA doubling time of less than 3 years, or upgrading (defined as increase in tumor volume (...) Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. Guidelines endorsing vegetable-enriched diets to improve outcomes for prostate cancer survivors are based on expert opinion, preclinical studies, and observational data.To determine the effect of a behavioral intervention that increased vegetable intake on cancer progression in men with early-stage prostate cancer.The Men's

2020 JAMA